21 results about "Glycosphingolipid" patented technology

The invention provides a method for detecting amino acid in a compound encephalokinin injection by using an LC-MS (Liquid Chromatography-Mass Spectrometry) method, which has the characteristics of simplicity and convenience in operation, and good precision, stability and recovery rate. The method can be used for detecting the content of 13 amino acids in the compound brain peptide injection, including histidine, phenylalanine, lysine, tyrosine, asparagine, methionine, valine, leucine, serine, arginine, proline, alanine and isoleucine. The detection method is high in detection sensitivity and can be applied to internal quality component research, intermediate component control and quality identification of the product. The detection method can also be used for evaluating the inherent quality of the compound encephalokinin injection, further ensuring the stability of the inherent quality of the product and providing technical reference.

This invention provides a sea cucumber ganglioside extract nanoliposome with neuroprotective activity and its preparation method. The preparation steps are as follows: thawed frozen ready-to-eat sea cucumber, chopped, freeze-dried, pulverized, and sieved to obtain freeze-dried powder. The powder is then extracted using supercritical CO2 extraction and rotary evaporation to remove the solvent. This powder is then dissolved in anhydrous ethanol with soybean lecithin and β-sitosterol as the oil phase, mixed with PBS buffer, stirred, and hydrated to obtain a proemulsion. After centrifugation, the precipitate is resuspended and sonicated to obtain the product. This invention uses supercritical CO2 extraction, and the extract contains 59.70 μg / g of gangliosides, with glycosphingolipids accounting for 96.372% of sphingolipids, resulting in enrichment of the target components. Simultaneously, these nanoliposomes significantly delay Aβ1-42-induced paralysis. The 30 μg / mL group showed a 2.75-fold increase in motor ability and a 30% increase in reproductive function compared to the control group, and a 47% reduction in ROS levels. The neuroprotective effect is superior to that of the unencapsulated extract, providing a new approach for adjuvant intervention in neurodegenerative diseases such as Alzheimer's disease, and has broad application prospects in the functional food field.

Arrhythmogenic cardiomyopathy (ACM) is a familial heart disease characterized by progressive myocardial fibrofatty infiltration. Compositions in the treatment of fibrofatty accumulation and its pathogenesis in ACM include activators of glycosphingolipid (GSL) glycosyltransferase, β-1,4-galactosyltransferase- V (β-1,4-GalT-V).

A composition for young children comprising glycosphingolipids. The present invention relates to a composition comprising one or more glycosphingolipids, to a nutritional formula for children comprising said composition, to the use of said composition for supporting healthy growth and development of young children, in particular infants, and for dietary management of symptoms related to inflammation of the gastrointestinal tract system of said young children. In particular, the present invention relates to a composition comprising one or more compounds of formula (1) or salts thereof: wherein R1 is a C13-C17 alkyl chain; r2 is a C15-C19 alkyl chain; and R3 is a glycosyl moiety selected from Neu5Ac [alpha] 2-3-Gal [beta] 1-4-Glc [beta] 1-or Neu5Ac [alpha] 2-8-Neu5Ac [alpha] 2-3-Gal [beta] 1-4-Glc [beta] 1-. Children's nutritional formulas comprising the composition are also provided.

The present invention relates to a method for producing a sialylated glycosphingolipid, comprising the steps of:-providing a glycosphingolipid, a sialic acid donor and an enzyme having transsialidase activity,-mixing the glycosphingolipid with the sialic acid donor in the presence of the enzyme having transsialidase activity, the sialylated glycosphingolipid is a sialylated glycosphingolipid, and wherein the sialic acid donor is 3 '-sialylated lactose.

In various embodiments, provided herein are host cells, methods, and pharmaceutical compositions, including complex sphingolipids, such as monosialic acid ganglioside 1 (GM1), monosialic acid ganglioside 2 (GM2), and monosialic acid ganglioside 3 (GM3). In some embodiments, the present disclosure provides biological production of glycosphingolipids. In still further embodiments, the present disclosure provides for the biological production of gangliosides.

The application relates to a sample processing method and a mass spectrometry detection method for selective photocatalytic desugar of glycosphingolipids. The sample processing method specifically comprises the following steps: (1) dissolving a sample in an alkaline protic solvent; (2) dispersing titanium dioxide particles in the sample; and (3) performing a photocatalytic reaction under ultraviolet light irradiation, centrifuging, and obtaining a photocatalytically processed sample solution. The mass spectrometry detection method specifically comprises the following steps: feeding the photocatalytically processed sample solution into a mass spectrometer to perform primary mass spectrometry detection, comparing the photocatalytically processed sample solution with a sample extraction solution without photocatalytic processing, screening a primary mass spectrometry peak that may be a glycolipid decomposition product through comparative analysis, and performing further secondary mass spectrometry detection to analyze the accurate molecular structure of the glycolipid. The method can selectively and rapidly and efficiently remove the sugar group head of glycolipids in the presence of complex lipid groups, and can be used for subsequent mass spectrometry detection and analysis. Through comparison of mass spectrometry peaks before and after removal, glycolipid peaks in complex mass spectrometry peaks can be effectively and rapidly and accurately found, important chemical information for rapid locking of correct candidate substances in the primary mass spectrometry qualitative process is provided, and glycolipid decomposition products can also obtain more abundant carbon chain structure information than original glycolipids to assist in qualitative analysis.

The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and / or other glucosylceramide-based glycosphingolipids (GSLs).

In various embodiments, host cells, methods, and pharmaceutical compositions comprising complex sphingolipids such as monosialoganglioside 1 (GM1), monosialoganglioside 2 (GM2), and monosialoganglioside 3 (GM3) are provided herein. In some embodiments, the disclosure provides the bioproduction of sphingoglycolipids. In yet another embodiment, the disclosure provides the bioproduction of gangliosides.

FIELD: cosmetics.SUBSTANCE: cosmetic composition in the form of a cream-gel for skin cleansing contains purified water; an emulsifier consisting of cetyl alcohol, glyceryl stearate, PEG-75 stearate, ceteth-20 and steareth-20; glycerin; coco-glucoside; a co-surfactant consisting of purified water, glyceryl oleate and coco-glucoside; cetearyl alcohol; caprylic / capric triglyceride; panthenol; butylene glycol; squalane; oat extract; sodium acrylate / sodium acryloyldimethyl taurate copolymer; cocamidopropyl betaine; cholesterol; ceramide complex including: ceramides NP, AP, AS, NG, glycosphingolipids, hydrogenated lecithin and auxiliary components; fructooligosaccharides; hydroxyacetophenone; preservative consisting of 1,2-hexanediol and caprylyl glycol; tocopheryl acetate; fragrance; arginine and disodium EDTA, in a certain ratio of components, wt.%.EFFECT: relisble removal of impurities from the skin's surface, restoration of the damaged protective barrier of the skin during washing without causing excessive dryness of the skin, relief of irritation and moisturization of the skin.1 cl, 3 tbl, 4 ex

The present invention describes a novel process for the isolation of glycosphingolipids lacking amide-linked fatty acyl groups, comprising the steps of providing a solution comprising the glycosphingolipids of formula (1) or salts thereof and one or more contaminants, percolating the solution by using a membrane having an MWCO of 100-300 kDa, separating the percolated glycosphingolipids from the percolated glycosphingolipids, and separating the percolated glycosphingolipids from the percolated glycosphingolipids. And separating the glycosphingolipids or salts thereof from one or more contaminants, thereby obtaining a diafiltration trapped fluid (DFR) comprising the glycosphingolipids or salts thereof, thereby separating the glycosphingolipids or salts thereof from the one or more contaminants.

Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, α-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided.

The present invention describes a novel method for isolating sphingoglycolipids lacking amide-linked fatty acid acyl groups. The method comprises the steps of: preparing a solution containing the sphingoglycolipid of formula (1) or a salt thereof and one or more impurities; and diafiltration the solution using a membrane having a MWCO of 100 kDa to 300 kDa to obtain a diafiltration retaining liquid (DFR) containing the sphingoglycolipid or salt thereof, thereby isolating the sphingoglycolipid or salt thereof from one or more impurities.

The present invention relates to the fusion proteins against a glycocalyx, found to be associated with several human post-translational modified proteins linked to cancer cell lines. The fusion proteins of the present invention are able to bind only to sialylated glycosphingolipids and sialylated glycoproteins and well as their independent constituents the monosaccharide sugars such as neu5ac, galnac and gal that constitute the glycocalyx. The products claimed can be used for diagnosis and treatment of various cancers. Apoptosis via Caspase 3 occurs in cancer cells when the fusion protein bound to targets is sequestered in lysosomes. The fusion protein is not seen in any other organelle of the cell except for lysosomes.

Provided are methods of synthesizing glycolipids. The methods combine chemical and enzymatic transformations to rapidly provide diverse natural and functionalized glycolipids in a high convergent matter. Stepwise enzymatic elongation of a carbohydrate chain of a common glycolipid precursor, compound (1), provides glycan intermediates of Formula (II), using sugar-nucleotides as glycosyl donors and glycosyltransferases as enzymes. Also provided are glycan intermediates of Formula (II) and alkene intermediates of Formula (IV) and methods of preparing same.

A composition comprising one or more compounds of formula (1), or salts thereof: (1) wherein R1 is a C13-C17 alkyl chain; R2 is a C15-C19 alkyl chain, preferably C18; and R3 is a glycosyl moiety selected from Neu5Acα2-3-Galβ1-4-Glcβ1-, or Neu5Acα2-8-Neu5Acα2-3- Galβ1-4-Glc β1-. Child nutritional formulas containing the composition are also provided.

The invention relates to the field of analytical chemistry and the field of lipidomics research, in particular to a method for omics analysis of acidic glycosphingolipids in animal brain tissues. The group analysis method comprises the following steps: firstly, extracting ganglioside and thioglycoside from animal brain tissues, carrying out C18 solid-phase extraction and enrichment, then carrying out qualitative analysis by using Nano-LC-Chip-Q-TOF-MS, carrying out analysis in combination with a QSRR model, and then carrying out quantitative analysis by using Nano-LC-Chip-QQQ-MS. The group analysis method is based on a Chip technology, combines C18 solid-phase extraction segmented enrichment and a QSRR model, greatly avoids ion inhibition and signal interference, has high resolution, high sensitivity and high accuracy, can accurately distinguish isomeride and same-weight elements, remarkably improves the detection efficiency and the structural identification and unknown substance prediction and quantification capability, and has a good application prospect. The defects of low-abundance component loss, narrow dynamic range and the like in the prior art are overcome.

The application discloses a glycosphingolipid separation and enrichment method and concentration, analysis and identification thereof, and the separation and enrichment method comprises the following steps: adding magnetic titanium dioxide nanomaterial and a sample to be separated into a loading buffer, incubating to obtain incubated materials; the sample to be separated contains glycosphingolipids and phospholipids, and the loading buffer comprises acetonitrile and ammonia water; the incubated materials are washed by using a washing buffer; the washing buffer comprises methanol, ammonia water and an ammonium salt; the washed materials are added into an elution buffer, incubated, and an eluent of glycosphingolipids is obtained. + The method utilizes the coordination interaction between glycosphingolipids and magnetic titanium dioxide nanomaterial, uses an alkaline aprotic solvent loading buffer and an alkaline protic solvent washing buffer, and introduces NH4 + , realizes specific separation and enrichment of glycosphingolipids, and can be used for Paternò-Büchi reaction and various liquid chromatography-mass spectrometry platforms to identify fine structures of glycosphingolipids.

Providing agents that promote the growth of Brautia species and agents that improve the intestinal environment. [Solution] The Brautia species growth promoter and intestinal environment improvement agent of the present invention both contain one selected from the group consisting of sphingoglycolipids and fiber derived from peaches as an active ingredient.

This invention relates to the field of chemical substance detection technology, specifically to a lipid in-situ mass spectrometry analysis method and apparatus based on online selective enrichment-photometric desorption. The method includes the following steps: (1) extracting lipids from the sample into an alkaline proton solvent using in-situ liquid extraction technology to obtain an in-situ extraction system solution; (2) drawing the in-situ extraction system solution through a transfer pipeline under vacuum or negative pressure for mass spectrometry detection, wherein a titanium dioxide nanoparticle coating is provided in the transfer pipeline; (3) after the lipid bands in the in-situ extraction system solution have been completely detected by mass spectrometry, irradiating the titanium dioxide nanoparticle coating with an ultraviolet lamp, continuing to pass an alkaline proton solvent, drawing it through the transfer pipeline for mass spectrometry detection. This invention enables online selective enrichment of glycolipids during in-situ liquid extraction, and direct desorption of glycosphingolipids using ultraviolet light without solvent switching, greatly improving the rate of glycosphingolipid desorption on the titanium dioxide surface and the ease of operation, ultimately improving the detection sensitivity of glycosphingolipids.

The application relates to the technical field of diagnosis and treatment of biomedical and ophthalmic diseases, and particularly relates to application of glycosphingolipid protein glycan-1 (Glypican-1, GPC1) in diagnosis and treatment of subretinal fibrosis, and the application is characterized in that GPC1 is found to be significantly changed in expression in a sample of a patient with subretinal fibrosis through proteomics screening, and it is verified through in-vivo and in-vitro experiments that GPC1 is up-regulated in expression in the process of subretinal fibrosis and plays a role in promoting fibrosis, thereby providing a new technical basis for early detection, risk assessment and targeted treatment of subretinal fibrosis.